ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
Key Highlights
- ➤ARR-217 delivered 44.8% ORR in late-line CRC patients at 6 mg/kg Q3W
- ➤ARR-217 achieved 93.1% DCR at 6 mg/kg Q3W in CRC patients
- ➤Phase 1b dose optimization advances at 5 and 6 mg/kg Q3W
- ➤Grade 3 or higher treatment-related adverse events affected 20.4% at 6 mg/kg
- ➤2027 dose optimization data expected for ArriVent’s lead ADC candidate
Expert Statements
Bing Yao, Ph.D., Chief Executive Officer of ArriVent
“These initial results reinforce our confidence in ARR-217 and in CDH17 as a potential therapeutic target for patients with gastrointestinal cancers who face limited treatment options following prior lines of therapy.”
Bing Yao, Ph.D., Chief Executive Officer of ArriVent
“We believe the responses observed in this heavily pretreated patient population, together with a manageable safety profile, provided a strong foundation for advancing ARR-217 into a Phase 1b dose optimization study.”
Bing Yao, Ph.D., Chief Executive Officer of ArriVent
“As the first ADC from our pipeline to enter clinical development, ARR-217 represents an important milestone for our ADC pipeline, and we look forward to dose optimization data expected in 2027.”
* 44.8% ORR at 6mg/kg dose in late-line CRC patients * ARR-217 was generally well-tolerated * ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program NEWTOWN SQUARE, Pa., Oct. 25, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced initial encouraging Phase 1 results for ARR-217, (MRG007), a cadherin-17 (CDH17)-targeting antibody-drug conjugate (ADC) developed in partnership with Lepu Biopharma Co., Ltd., in patients with gastrointestinal malignancies. The findings were presented as part of an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress 2026.
"These initial results reinforce our confidence in ARR-217 and in CDH17 as a potential therapeutic target for patients with gastrointestinal cancers who face limited treatment options following prior lines of therapy," said Bing Yao, Ph.D., Chief Executive Officer of ArriVent. "We believe the responses observed in this heavily pretreated patient population, together with a manageable safety profile, provided a strong foundation for advancing ARR-217 into a Phase 1b dose optimization study. As the first ADC from our pipeline to enter clinical development, ARR-217 represents an important milestone for our ADC pipeline, and we look forward to dose optimization data expected in 2027."
Get started
Create a free account to read the full story.